Evolent Health (EVH) Tops Q3 EPS by 23c; Offers FY23 Revenue Guidance

Evolent Health (NYSE: EVH) reported Q3 EPS of $0.30, $0.23 better than the analyst estimate of $0.07. Revenue for the quarter came in at $511 million versus the consensus estimate of $509.21 million.

GUIDANCE:

Evolent Health sees FY2023 revenue of $1.95-1.97 billion, versus the consensus of $1.95 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c